In both the LUSC and LUAD cohorts, the FLT3‐high expression group had higher infiltration of all assessed immune cells (T cells, T cells CD8+, cytotoxic score, NK cells, B cells, monocytes, macrophages, myeloid dendritic cells, neutrophils, endothelial cells) and cancer‐associated fibroblasts compared to the FLT3‐low expression group (Table S1, Fig. 2). The gene discussed is FLT3; the disease is cancer.